Amy Greenblatt
Research Triangle Park
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amy Greenblatt.
American Journal of Preventive Medicine | 2013
Catherine A Forneris; Gerald Gartlehner; Kimberly A Brownley; Bradley N Gaynes; Jeffrey Sonis; Emmanuel Coker-Schwimmer; Daniel E Jonas; Amy Greenblatt; Tania M Wilkins; Carol Woodell; Kathleen N. Lohr
CONTEXT Traumatic events are prevalent worldwide; trauma victims seek help in numerous clinical and emergency settings. Using effective interventions to prevent post-traumatic stress disorder (PTSD) is increasingly important. This review assessed the efficacy, comparative effectiveness, and harms of psychological, pharmacologic, and emerging interventions to prevent PTSD. EVIDENCE ACQUISITION The following sources were searched for research on interventions to be included in the review: MEDLINE; Cochrane Library; CINAHL; EMBASE; PILOTS (Published International Literature on Traumatic Stress); International Pharmaceutical Abstracts; PsycINFO; Web of Science; reference lists of published literature; and unpublished literature (January 1, 1980 to July 30, 2012). Two reviewers independently selected studies, extracted data or checked accuracy, assessed study risk of bias, and graded strength of evidence. All data synthesis occurred between January and September 2012. EVIDENCE SYNTHESIS Nineteen studies covered various populations, traumas, and interventions. In meta-analyses of three trials (from the same team) for people with acute stress disorder, brief trauma-focused cognitive behavioral therapy was more effective than supportive counseling in reducing the severity of PTSD symptoms (moderate-strength); these two interventions had similar results for incidence of PTSD (low-strength); depression severity (low-strength); and anxiety severity (moderate-strength). PTSD symptom severity after injury decreased more with collaborative care than usual care (single study; low-strength). Debriefing did not reduce incidence or severity of PTSD or psychological symptoms in civilian traumas (low-strength). Evidence about relevant outcomes was unavailable for many interventions or was insufficient owing to methodologic shortcomings. CONCLUSIONS Evidence is very limited regarding best practices to treat trauma-exposed individuals. Brief cognitive behavioral therapy may reduce PTSD symptom severity in people with acute stress disorder; collaborative care may help decrease symptom severity post-injury.
American Journal of Preventive Medicine | 2013
Catherine A Forneris; Gerald Gartlehner; Kimberly A Brownley; Bradley N Gaynes; Jeffrey Sonis; Emmanuel Coker-Schwimmer; Daniel E Jonas; Amy Greenblatt; Tania M Wilkins; Carol Woodell; Kathleen N. Lohr
CONTEXT Traumatic events are prevalent worldwide; trauma victims seek help in numerous clinical and emergency settings. Using effective interventions to prevent post-traumatic stress disorder (PTSD) is increasingly important. This review assessed the efficacy, comparative effectiveness, and harms of psychological, pharmacologic, and emerging interventions to prevent PTSD. EVIDENCE ACQUISITION The following sources were searched for research on interventions to be included in the review: MEDLINE; Cochrane Library; CINAHL; EMBASE; PILOTS (Published International Literature on Traumatic Stress); International Pharmaceutical Abstracts; PsycINFO; Web of Science; reference lists of published literature; and unpublished literature (January 1, 1980 to July 30, 2012). Two reviewers independently selected studies, extracted data or checked accuracy, assessed study risk of bias, and graded strength of evidence. All data synthesis occurred between January and September 2012. EVIDENCE SYNTHESIS Nineteen studies covered various populations, traumas, and interventions. In meta-analyses of three trials (from the same team) for people with acute stress disorder, brief trauma-focused cognitive behavioral therapy was more effective than supportive counseling in reducing the severity of PTSD symptoms (moderate-strength); these two interventions had similar results for incidence of PTSD (low-strength); depression severity (low-strength); and anxiety severity (moderate-strength). PTSD symptom severity after injury decreased more with collaborative care than usual care (single study; low-strength). Debriefing did not reduce incidence or severity of PTSD or psychological symptoms in civilian traumas (low-strength). Evidence about relevant outcomes was unavailable for many interventions or was insufficient owing to methodologic shortcomings. CONCLUSIONS Evidence is very limited regarding best practices to treat trauma-exposed individuals. Brief cognitive behavioral therapy may reduce PTSD symptom severity in people with acute stress disorder; collaborative care may help decrease symptom severity post-injury.
Addiction | 2014
James C. Garbutt; Amy Greenblatt; Suzanne L. West; Laura C Morgan; Alexei B. Kampov-Polevoy; Harmon S. Jordan; Georgiy Bobashev
AIM The goal of this systematic review was to identify moderators of naltrexone efficacy in the treatment of alcohol dependence. METHODS We searched Pubmed, CINHAL, Embase, PsycINFO and the Cochrane Library from 1990 to April 2012 and reference lists of pertinent review articles, which yielded 622 trial, pooled analysis and review articles. Using pre-established eligibility criteria, two reviewers independently determined whether abstracts contained evidence of demographic or biological characteristics, i.e. moderators, influencing naltrexone response in alcohol dependence. We assessed each publication for risk of bias and evaluated the strength of the body of evidence for each moderator. RESULTS Twenty-eight publications (on 20 studies) met criteria for data synthesis. These included 26 publications from 12 randomized, placebo-controlled trials, three non-randomized, non-placebo studies and one randomized, non-placebo study. In addition, there were two publications from pooled analyses of four randomized, placebo-controlled trials. Family history of alcohol problems and the Asn40Asp polymorphism of the μ-opioid receptor gene showed a positive association with efficacy in four of five and three of five studies, respectively. Other moderators reported to be associated with efficacy included male sex (two of five studies), pre-treatment drinking (two of two studies) and high craving (two of five studies). However, the overall risk of bias in the published literature is high. CONCLUSIONS The identification of naltrexone-responsive alcohol-dependent patients is still in development. Studies to date point to two potential moderators-family history and presence of the OPRM1 Asn40Asp polymorphism-as having the strongest evidence. However, the data to date is still insufficient to recommend that any moderator be used in determining clinical treatment.
Clinical Psychology Review | 2016
Karen Cusack; Daniel E Jonas; Catherine A Forneris; Candi Wines; Jeffrey Sonis; Jennifer Cook Middleton; Cynthia Feltner; Kimberly A Brownley; Kristine Rae Olmsted; Amy Greenblatt; Amy Weil; Bradley N Gaynes
Drug Safety | 2014
Ursula Reichenpfader; Gerald Gartlehner; Laura C Morgan; Amy Greenblatt; Barbara Nussbaumer; Richard A. Hansen; Megan Van Noord; Linda J Lux; Bradley N Gaynes
Series:AHRQ Comparative Effectiveness Reviews | 2013
Daniel E Jonas; Karen Cusack; Catherine A Forneris; Tania M Wilkins; Jeffrey Sonis; Jennifer Cook Middleton; Cynthia Feltner; Dane Meredith; Jamie Cavanaugh; Kimberly A Brownley; Kristine Rae Olmsted; Amy Greenblatt; Amy Weil; Bradley N Gaynes
Cochrane Database of Systematic Reviews | 2015
Barbara Nussbaumer; Angela Kaminski-Hartenthaler; Catherine A Forneris; Laura C Morgan; Jeffrey Sonis; Bradley N Gaynes; Amy Greenblatt; Jörg Wipplinger; Linda J Lux; Dietmar Winkler; Megan Van Noord; Julia Hofmann; Gerald Gartlehner
Cochrane Database of Systematic Reviews | 2015
Angela Kaminski-Hartenthaler; Barbara Nussbaumer; Catherine A Forneris; Laura C Morgan; Bradley N Gaynes; Jeffrey Sonis; Amy Greenblatt; Jörg Wipplinger; Linda J Lux; Dietmar Winkler; Megan Van Noord; Julia Hofmann; Gerald Gartlehner
Series:AHRQ Comparative Effectiveness Reviews | 2013
Nancy D Berkman; Ina Wallace; Michael J. Steiner; Melody Harrison; Amy Greenblatt; Kathleen N. Lohr; Adam J. Kimple; Andrea Yuen
CNS Drugs | 2014
Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A. Hansen; Megan Van Noord; Linda J Lux; Bradley N Gaynes; Gerald Gartlehner